---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-107219"
form_type: "8-K"
ticker: "APRE"
cik: "0001781983"
company_name: "Aprea Therapeutics, Inc."
filed_at: "2024-10-09T23:59:59+00:00"
generated_at: "2026-05-30T17:26:26.866849+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aprea reports preliminary cash of $26.2M; CMO Mirza steps down, engages Dr. Pultar as advisor

## Summary
- Preliminary cash and equivalents ~$26.2M as of Sep 30, 2024, down from $28.7M at Jun 30, 2024.
- Dr. Nadeem Mirza steps down as CMO effective Oct 9, 2024; will remain through Dec 13, 2024.
- Engaged Dr. Philippe Pultar as Senior Medical Advisor to lead WEE1 inhibitor APR-1051 Phase 1 trial.
- Patient enrollment ongoing in Phase 1 ACESOT-1051 study for APR-1051; update expected by year-end 2024.

## SEC filing metadata
- accession: 0001104659-24-107219
- form_type: 8-K
- ticker: APRE
- cik: 0001781983
- company_name: Aprea Therapeutics, Inc.
- filed_at: 2024-10-09T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781983/000110465924107219/0001104659-24-107219-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781983/000110465924107219/tm2425851d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-107219
- JSON: https://secwatch.observer/filing/0001104659-24-107219.json
- Plain text: https://secwatch.observer/filing/0001104659-24-107219.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.